Characterization of vascular gene transfer using a novel cationic lipid.

INTRODUCTION Cationic liposomes are an alternative non-viral vector for gene therapy, but several factors affect transfection efficiency. A novel cationic lipid, o-ethyldioleoylphosphatidylcholinium (EDOPC), was studied for characterization of the time course and effects of lipid composition, concentration, charge ratio, mixing techniques, passage number, and stimulated state on transfection of human vascular cells, represented by human umbilical vein endothelial cells (HUVEC). METHODS HUVEC cultures were seeded at a density of 45,000 cells/well in 24-well plates and incubated overnight. Triplicate wells were transfected with samples of EDOPC/reporter plasmid for 2 h, followed by a 24-h expression time, which was the peak expression time point in an initial time-course experiment. Measuring luciferase in cell lysates quantitated gene expression. RESULTS Transfection of HUVEC with EDOPC was optimal with a concentration of 100 microgram lipid/well, ratio of 3:1 EDOPC:plasmid, fractional mixing of lipid and plasmid, centrifugation, and incubation in serum-free media. Transfections in sequential passages showed striking decreases in gene expression and regression analysis revealed the relationship: RLU = 120,000 - (10, 400 x passage number), r(2) = 0.947. HUVEC activated by cytokine stimulation remain susceptible to gene transfer specifically with EDOPC. SUMMARY During transfection of HUVEC with cationic lipid species, an increase in passage number is associated with linear reduction in luciferase expression, and hence passage number must be controlled in comparative experiments. Characteristics of EDOPC may permit site-specific efficient transfection of activated human vascular cells that can be isolated from serum by mechanical methods.

[1]  M. Rekhter,et al.  Graft permeabilization facilitates gene therapy of transplant arteriosclerosis in a rabbit model. , 1998, Circulation.

[2]  K. Channon,et al.  Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries: impact on transgene expression and endothelial function. , 1998, Circulation research.

[3]  K Walsh,et al.  Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. , 1998, Circulation.

[4]  J. Polak,et al.  The PREVENT Trial of vein graft genetic engineering Preliminary molecular and clinical findings , 1998 .

[5]  B. Davidson,et al.  Augmented adenovirus-mediated gene transfer to atherosclerotic vessels. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[6]  M. Makuuchi,et al.  Adenovirus-mediated transfer of tissuetype plasminogen activator gene to human endothelial cells , 1997 .

[7]  T. Welling,et al.  Improved retroviral transduction efficiency of vascular cells in vitro and in vivo during clinically relevant incubation periods using centrifugation to increase viral titers. , 1997, Journal of vascular surgery.

[8]  M. Keogh,et al.  High efficiency reporter gene transfection of vascular tissue in vitro and in vivo using a cationic lipid–DNA complex , 1997, Gene Therapy.

[9]  J. Behr,et al.  Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. , 1996, Gene therapy.

[10]  R. Virmani,et al.  Local adenoviral–mediated expression of recombinant hirudin reduces neointima formation after arterial injury , 1996, Nature Medicine.

[11]  J. Stanley,et al.  Retroviral vector-mediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells. , 1995, Journal of vascular surgery.

[12]  F. Veith,et al.  Human transluminally placed endovascular stented grafts: preliminary histopathologic analysis of healing grafts in aortoiliac and femoral artery occlusive disease. , 1995, Journal of vascular surgery.

[13]  J. Seltzer,et al.  Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product , 1995, Science.

[14]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Isner,et al.  Increased gene expression after liposome-mediated arterial gene transfer associated with intimal smooth muscle cell proliferation. In vitro and in vivo findings in a rabbit model of vascular injury. , 1994, The Journal of clinical investigation.

[16]  J. Isner,et al.  Liposome-mediated gene transfer into human vascular smooth muscle cells. , 1994, Circulation.

[17]  E. Nabel,et al.  Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo , 1993, Nature.

[18]  J. Isner,et al.  Percutaneous arterial gene transfer in a rabbit model. Efficiency in normal and balloon-dilated atherosclerotic arteries. , 1992, The Journal of clinical investigation.

[19]  D. Dichek,et al.  Seeding of intravascular stents with genetically engineered endothelial cells. , 1989, Circulation.

[20]  J. Northrop,et al.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.